PURPOSE: The purpose of our study is to assess CNV profiles of CTCs and matched primary

tumor samples as biomarkers for malignant potential and risk of HCC recurrence. METHODS: Serum and tumor samples were collected from 100 patients over three years. Peripheral blood samples collected before, at the time of, and at multiple points after surgery were analyzed for CTCs. CTCs isolated from the peripheral blood were identified using a high definition CTC assay and primary tumor tissues were sampled as touch preps. The genomes of the isolated CTC and touch prep single cells GDC-0973 cell line were amplified and sequenced to determine genome wide CNV profiles (single cell genomic analysis). RESULTS: Presently, 45 patients have undergone total hepatectomy with liver transplantation and 16 partial hepatic resections for HCC with 3 episodes of recurrence to date. One patient recurred after partial hepatectomy and two after transplant. CTC levels varied between patients and at different times in the clinical course. Over 80% of CTCs and primary tumor cells identified were successfully isolated, and genetically amplified for CNV profiling. CNV profiles of different cell populations from the same patient often had similar mutation patterns. Some of those mutations identified have been

associated with more aggressive malignancy. CONCLUSION: We successfully demonstrated Lenvatinib concentration the ability to perform high-content CNV analysis of single cells from primary HCC tumors and CTCs in patients with tumor recurrence following definitive surgical

therapy. The initial success of this pilot study suggests that CNV analysis of CTCs may prove beneficial in predicting risk of HCC recurrence after liver transplantation or resection. A comprehensive study to further investigate is currently underway. Disclosures: Kelly Bethel – Consulting: Epic Sciences, Inc; Stock Shareholder: Epic Sciences, Inc Peter Kuhn – Stock Shareholder: Epic Sciences The following people have nothing to selleck products disclose: Jennifer Au, Angel E. Dago, Randolph L. Schaffer Background: Hepatocellular carcinoma (HCC) has a poor prognosis due to widespread intrahepatic and extrahepatic metastasis. There is a need to understand signaling cascades that promote disease progression. Aspartyl-(Asparaginyl) -β-hydroxylase (ASPH) is known to be overexpressed in human HCC and correlates with poor prognosis and survival following surgery. We developed a small molecule as an ASPH inhibitor and preclinically evaluated its efficacy for HCC in vitro and in vivo. Methods: Levels of ASPH expression were evaluated by immunohistochemistry (IHS) in human HCC tumors included dysplastic nodules and adjacent normal liver. Small molecule inhibitors (SMIs) were designed based on the crystal structure of the ASPH catalytic site followed by computer assisted drug design. In order to test candidate compounds for inhibition of β-hydroxylase activity, a CO2 capture assay was performed.